Calyxo Raises $40M Series F to Expand Kidney Stone Treatment Platform and CVAC System Adoption
Kidney stone treatment has been playing a quiet game of compromise for years. Technology improved, procedures evolved, but outcomes still carried a familiar asterisk. Fragments left behind. Follow-ups nobody wanted. Costs that kept echoing long after the operating room lights dimmed. In the startup ecosystem, those are the inefficiencies that don’t just invite disruption, they demand it.
Calyxo, Inc. just moved deeper into that gap with a $40M Series F round, reinforcing what happens when clinical validation meets sustained capital support. Founded in 2016 and headquartered in Pleasanton, California, the company has centered its strategy around the CVAC System, an all-in-one platform that integrates ureteroscopy, laser lithotripsy, irrigation, and vacuum aspiration into a single device. The objective is straightforward and measurable: complete stone clearance, not partial progress.
Jee Shin, Founder and Chief Business Officer, and Joe Catanese III, PhD, President and CEO, have built the company around that premise, with Ally Bridge Group and Janus Henderson Investors leading this round and Questa Capital, Avidity Partners, and CRG returning. That investor composition signals continued institutional confidence, particularly as clinical outcomes and utilization data begin to compound inside the startup ecosystem.
Performance metrics are doing the heavy lifting. More than 40,000 patients treated to date. A 96% mean stone clearance rate reported in the CLEARANCE study. Residual stone volume measured at 14.1 mm³ at 30 days, independent of initial stone burden. 2-year ASPIRE data showed a 73% reduction in unplanned healthcare consumption events compared to standard ureteroscopy, with 3 events versus 20. The implication is direct: fewer complications, fewer follow-ups, and lower downstream cost exposure.
The SURE procedure, Steerable Ureteroscopic Renal Evacuation, operationalizes that advantage through continuous evacuation during and after lithotripsy. It shifts the procedure from fragmentation to full clearance within the same workflow. In a U.S. market exceeding 1.1M ureteroscopy procedures annually, that distinction becomes commercially relevant at scale, not just clinically interesting.
The $40M will be deployed across commercial expansion, clinical and health economic evidence generation, and continued platform development. Increased surgeon adoption, broader facility penetration, and expanded data sets are all part of the same equation: converting validated performance into standard practice. That is how companies transition from product to protocol within the startup ecosystem.
Calyxo is positioning around a single outcome that the market already understands but has not consistently achieved. Complete clearance, backed by data, delivered at scale, and increasingly difficult to ignore.
